CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 52 enrolled
Drug / intervention
axitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00828919
NCT00828919N/ACompleted
CompareCT.gov

CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2, AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 IN CLINICAL TRIALS

Pfizer·interventional·Posted Jan 26, 2009·Updated Dec 3, 2024

In Brief

A clinical study evaluating axitinib and crizotinib for Solid Tumors. Completed, enrolled 52 participants across 34 sites in 11 countries.

Detailed Summary

To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesCzechia, France, Germany, Hungary, Italy, Japan, Russia, South Korea, Taiwan, United Kingdom, United States
Collaborators--

Timeline

N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 26, 2009
Enrollment StartMar 7, 2003
Primary CompletionAug 14, 2023
TodayJul 2, 2026
Enrollment to primary: 20.4 yearsPosted 17.4 years ago

Interventions

axitinibdrug

BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial

crizotinibdrug

BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.